BioCentury | Jul 5, 2010

Quogue capitalizes Calistoga: Cancer play Calistoga adds $40M from VCs on top of $30M in 2009

Quogue capitalizes Calistoga Wayne Rothbaum of Quogue Capital ventured out of his usual territory of biotech public market investment to lead last week's $40 million series C round for cancer and inflammatory disease company Calistoga...
BC Innovations | Mar 18, 2010
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Phosphoinositide 3-kinase (PI3K) A study in human cell culture identified quinazolinone-based dual PI3K catalytic subunit-d- and catalytic subunit-g-selective inhibitors that could help treat inflammation...
BioCentury | May 11, 2009

Ebb & Flow

What a difference a product approval makes. Activist investor Kevin Tang terminated his threatened proxy battle with Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and withdrew his proposal to liquidate the company after FDA approved the biotech's Fanapt...
Items per page:
1 - 3 of 3